RUDN chemist, along with colleagues from the RAS Institutes, simplified the synthesis of antitumor compounds

RUDN chemist, along with colleagues from the RAS Institutes, simplified the synthesis of antitumor compounds

A RUDN chemist in collaboration with colleagues from N.D. Zelinsky Institute of Organic Chemistry and N.K. Koltsov Institute of Developmental Biology (IDB), RAS have developed a new method for the synthesis of isoxazole derivatives — substances that destabilize the process of cell division and potentially may become the basis for new anti-cancer drugs. The new method is based on the use of easily available reagents and does not require high temperatures.

Many modern anticancer drugs are toxic, difficult to access and/or very expensive. Moreover, tumor cells may develop resistance to the drugs used. Therefore, researchers study the biological properties of molecules in order to obtain new antitumor drugs with optimal properties. One of the common approaches to the search for such drugs is testing of analogues of substances that already showed antitumor activity. Such substances include, in particular, isoxazole derivatives that inhibit — “turn off” — the Hsp90 protein, which is necessary for the survival of tumor cells. However, compounds of this class are inaccessible due to the complexity of the synthesis procedure, which requires, in particular, the complete absence of water molecules, and the reagents are expensive and toxic.

RUDN chemist Viktor Khrustalev and his colleagues developed a method for the synthesis of isomers of these substances, that is, the compounds that are identical in atomic composition but different in the arrangement of atoms in space. Easily accessible derivatives of arylnitromethanes and chloroacetamides were used as raw materials, and the reaction itself was carried out at temperatures not exceeding 80 degrees at atmospheric pressure and did not require anhydrous conditions.

The obtained substances had anticancer activity, but unlike the prototype compounds, they did not inhibit Hsp90 protein. Their mechanism of action is based on the destabilization of the cell division process as they prevent the formation of microtubules, which are important in the process of cell division.

Taxol derivatives, one of the most commonly used antitumor agents, have the same mechanism of action. Basing on the compounds obtained by the scientists, it is possible to create a substitute for an expensive, inaccessible and highly toxic derivatives of taxol in the treatment of cancer.

The work was published in European Journal of Organic Chemistry.

All news
22 Oct
A Chemist from RUDN University Developed a New Method for Combating Antibiotic Resistance in Microbes

Bacteria in biofilms are 1,000 times more resistant to antibiotics, disinfectants, mechanical treatment, and other types of stress. A chemist from RUDN University suggested a method to prevent the formation of biofilms and reduce the resistance of bacteria to antimicrobial medications. This might help increase the efficiency of antibacterial treatment in the food industry, medicine, and agriculture.

20 Oct
RUDN University Professor Suggested how to Clean Up Space Debris

A specialist in spacecraft movement control analyzed the process of placing vehicle stages, boosters, and other space debris into the so-called disposal orbit and suggested cleaning lower orbits up with a spacecraft that has modules with engine units on board. These modules will attach to space debris objects and move them away. As for the geostationary orbit, a preferable way to clean it up would be a towing spacecraft that transports space debris objects into the disposal orbit.

14 Oct
A Biologist from RUDN University Found Sex Differences in Inflammatory Reactions in Rat Pups

A biologist from RUDN University studied the development of the immune response in prepubertal male and female animals. According to her, the severity and mortality of infectious and inflammatory diseases at this age depend not on the sex hormones, but mainly on the chromosome set or karyotype.